Gland Pharma Ltd has posted a 12 per cent year-on-year rise in profit after tax (PAT) at Rs 84 crore for the quarter ended September 2025, supported by robust contributions from its CDMO subsidiary, Cenexi. In the same period last fiscal, the Hyderabad-based pharmaceutical firm had reported a PAT of Rs 163 crore. Revenue from operations grew to Rs 1,487 crore in the July–September quarter, compared to Rs 1,406 crore in the corresponding quarter of the previous fiscal, the company said. "Gland Pharmadelivered a strong first half of FY26, with Revenue growth of 7% and PAT up by 30% YoY.We expect stronger momentum in the second half, driven by new launches and Cenexi's recovery. Our investments in global CDMO expansion, capacity enhancement in high-end modalities and complex injectables pipeline continue to strengthen our foundation and support sustainable growth and long-term value for all stakeholders," Gland Pharma Executive Chairman Srinivas Sadu said.
Disclaimer: This website is designed for healthcare professionals and serves solely for informational purposes.
The content provided should not be interpreted as medical advice, diagnosis, treatment recommendations, prescriptions, or endorsements of specific medical practices. It is not a replacement for professional medical consultation or the expertise of a licensed healthcare provider.
Given the ever-evolving nature of medical science, we strive to keep our information accurate and up to date. However, we do not guarantee the completeness or accuracy of the content.
If you come across any inconsistencies, please reach out to us at
admin@doctornewsdaily.com.
We do not support or endorse medical opinions, treatments, or recommendations that contradict the advice of qualified healthcare professionals.
By using this website, you agree to our
Terms of Use,
Privacy Policy, and
Advertisement Policy.
For further details, please review our
Full Disclaimer.
0 Comments
Post a comment
No comments yet. Be the first to comment!